Skip to main content
. 2023 Jan 9;184(4):370–375. doi: 10.1159/000528343

Table 3.

Intravenous desensitization protocol of Case 3

Solution type Solution content Concentration
A 10 mL solution B + 90 mL 0.9% NaCl 0.002 mg/mL (1/1,000)
B 10 mL solution C + 90 mL 0.9% NaCl 0.02 mg/mL (1/100)
C 10 mL solution D + 90 mL 0.9% NaCl 0.2 mg/mL (1/10)
D 140 mL drug (700 mg) +210 mL 0.9% NaCl 2 mg/mL (1/1)
Step Solution type Rate, mL/h Infusion duration, min Volume infused per step, mL Dose administered with this step, mg Cumulative dose, mg
1 A 2 15 0.5 0.001 0.001
2 A 4 15 1 0.002 0.003
3 A 8 15 2 0.004 0.007
4 A 16 15 4 0.008 0.015
5 B 4 15 1 0.02 0.035
6 B 8 15 2 0.04 0.075
7 B 16 15 4 0.08 0.155
8 B 32 15 8 0.16 0.315
9 C 8 15 2 0.4 0.715
10 C 16 15 4 0.8 1.515
11 C 32 15 8 1.6 3.115
12 C 64 15 16 3.2 6.315
13 D 16 15 4 4 14.31
14 D 32 15 8 16 30.31
15 D 52 15 13 26 56.31
16 D 52 341 296 592 648

Dose: 40 mg/kg/day; the patient's weight: 16.2 kg; total volume: 373.5 mL. NaCI, sodium chloride; alglucosidase alfa (Myozime®) = 50 mg = 10 mL.